FDA 483 - Apitoria Pharma Private Limited - August 01, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The FDA inspected Aurobindo Pharma Limited, Unit XI, an API manufacturer in Pydibhimavaram, India, revealing significant quality system deficiencies. Observations included inadequate equipment cleaning procedures leading to visible residue and rust, a failure to thoroughly investigate numerous instrument errors and a market complaint, and a lack of adherence to quality control unit procedures for deviation initiation and contemporaneous data recording. These issues indicate a concerning lack of control over manufacturing processes and quality systems.
ID · a74f3cff-2b7b-49cd-b3b8-759a5b3ea22d